Dietary Aflatoxin Exposure and Chemoprevention of Cancer: A Clinical Review

References

• Wilson DM, Mubatanhema W, Jurjevic Z. Biology and ecology of mycotoxigenic Aspergillus species as related to economic and health concerns. Adv Exp Med Biol 2002; 504: 3–17
   PubMed Web of Science ®Google Scholar
• Krishnamachari KA, Bhat RV, Nagarajan V, Tilak TB. Hepatitis due to aflatoxicosis. An outbreak in Western India. Lancet 1975; 1: 1061–1063
   PubMed Web of Science ®Google Scholar
• Tandon BN, Krishnamurthy L, Koshy A, Tandon HD, Ramalingaswami V, Bhandari JR, Mathur MM, Mathur PD. Study of an epidemic of jaundice, presumably due to toxic hepatitis, in Northwest India. Gastroenterology 1977; 72: 488–494
   PubMed Web of Science ®Google Scholar
• Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, Wogan GN, Groopman JD. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3: 3–10
   PubMed Web of Science ®Google Scholar
• Mycotoxins. Some Naturally Occurring Substances: Food Items and Constituents, Heterocyclic Aromatic Amines and Mycotoxins. IARC, Lyon 1993; Vol. 56: 397–488
   Google Scholar
• Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, Groopman JD, Gao YT, Henderson BE. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943–946
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou T, Wild CP, Xia XL, Baffoe-Bonnie A, Ofori-Adjei D. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA 1995; 92: 2384–2387
   PubMed Web of Science ®Google Scholar
• Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, Tsai WY, Santella RM. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 1997; 57: 3471–3477
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Johnson WW, Shimada T, Ueng YF, Yamazaki H, Langouet S. Activation and detoxication of aflatoxin B1. Mutat Res 1998; 402: 121–128
   PubMed Web of Science ®Google Scholar
• , Food and Agriculture Organization, World Health Organization. Joint FAO/WHO Expert Committee on Food Additives 2001; 1–33, 2–15.
   Google Scholar
• Guengerich FP. Forging the links between metabolism and carcinogenesis. Mutat Res 2001; 488: 195–209
   PubMed Web of Science ®Google Scholar
• Gan LS, Skipper PL, Peng XC, Groopman JD, Chen JS, Wogan GN, Tannenbaum SR. Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1. Carcinogenesis 1988; 9: 1323–1325
   PubMed Web of Science ®Google Scholar
• Sabbioni G, Ambs S, Wogan GN, Groopman JD. The aflatoxin–lysine adduct quantified by high-performance liquid chromatography from human serum albumin samples. Carcinogenesis 1990; 11: 2063–2066
   PubMed Web of Science ®Google Scholar
• Wild CP, Turner PC. Exposure biomarkers in chemoprevention studies of liver cancer. IARC Sci Publ 2001; 154: 215–222
   PubMedGoogle Scholar
• Wild CP, Hudson GJ, Sabbioni G, Chapot B, Hall AJ, Wogan GN, Whittle H, Montesano R, Groopman JD. Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1992; 1: 229–234
   PubMed Web of Science ®Google Scholar
• McLean M, Dutton MF. Cellular interactions and metabolism of aflatoxin: an update. Pharmacol Ther 1995; 65: 163–192
   PubMed Web of Science ®Google Scholar
• Hsieh DPH, Wong ZA, Wong JJ, Michas C, Ruebner BH. Comparative metabolism of aflatoxins. Mycotoxins in Human and Animal Health, JV Rodricks, CWMM Hesseltine. Pathotox Publishers, Illinois 1977; 37–51
   Google Scholar
• Egner PA, Wang JB, Zhu YR, Zhang BC, Wu Yan, Zhang QN, Qian GS, Kuang SY, Gange SJ, Jacobson LP, Helzlsouer KJ, Bailey GS, Groopman JD, Kensler TW. Chlorophyllin intervention reduces aflatoxin–DNA adducts in individuals at high risk for liver cancer. PNAS 2001; 98(25)14601–14606
   PubMed Web of Science ®Google Scholar
• Groopman JD, Kensler TW. The light at the end of the tunnel for chemical-specific biomarkers: daylight or headlight?. Carcinogenesis 1999; 20: 1–11
   PubMed Web of Science ®Google Scholar
• de Vries HR, Maxwell SM, Hendrickse RG. Aflatoxin excretion in children with Kwashiorkor or marasmic Kwashiorkor—a clinical investigation. Mycopathologia 1990; 110: 1–9
   PubMed Web of Science ®Google Scholar
• Bailey EA, Iyer RS, Stone MP, Harris TM, Essigmann JM. Mutational properties of the primary aflatoxin B1-DNA adduct. Proc Natl Acad Sci USA 1996; 93: 1535–1539
   PubMed Web of Science ®Google Scholar
• Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427–428
   PubMed Web of Science ®Google Scholar
• Mace K, Aguilar F, Wang JS, Vautravers P, Gomez-Lechon M, Gonzalez FJ, Groopman J, Harris CC, Pfeifer AM. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 1997; 18(7)1291–1297
   PubMed Web of Science ®Google Scholar
• Wild CP, Fortuin M, Donato F, Whittle HC, Hall AJ, Wolf CR, Montesano R. Aflatoxin, liver enzymes, and hepatitis B virus infection in Gambian children. Cancer Epidemiol Biomarkers Prev 1993; 2: 555–561
   PubMed Web of Science ®Google Scholar
• Li D, Cao Y, He L, Wang NJ, Gu JR. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 1993; 14: 169–173
   PubMed Web of Science ®Google Scholar
• Stern MC. Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev 2001; 10(6)617–625
   PubMed Web of Science ®Google Scholar
• Cheng Z, Root M, Pan W, Chen J, Campbell TC. Use of an improved method for analysis of urinary aflatoxin M1 in a survey of mainland China and Taiwan. Cancer Epidemiol Biomarkers Prev 1997; 6: 523–529
   PubMed Web of Science ®Google Scholar
• Groopman JD, Hall AJ, Whittle H, Hudson GJ, Wogan GN, Montesano R, Wild CP. Molecular dosimetry of aflatoxin-N7-guanine in human urine obtained in The Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1992; 1: 221–227
   PubMed Web of Science ®Google Scholar
• Wang JS, Shen X, He X, Zhu YR, Zhang BC, Wang JB, Qian GS, Kuang SY, Zarba A, Egner PA, Jacobson LP, Munoz A, Helzlsouer KJ, Groopman JD, Kensler TW. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999; 91(4)347–354
   PubMed Web of Science ®Google Scholar
• Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, Wu MH, Wu WP, Wang LW, Wang Q, Huang GT, Yang PM, Lee HS, Santella RM. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996; 67: 620–625
   PubMed Web of Science ®Google Scholar
• Kensler TW, Davis EF, Bolton MG. Strategies for chemoprotection against aflatoxin-induced liver cancer. The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance, DL Eaton, JD Groopman. Academic Press, New York 1994; 281–306
   Google Scholar
• Benson AB, III. Oltipraz: a laboratory and clinical review. J Cell Biochem 1993; Supplement 17F: 278–291
   Google Scholar
• Archer S. The chemotherapy of schistosomiasis. Annu Rev Pharmacol Toxicol 1985; 25: 485–508
   PubMed Web of Science ®Google Scholar
• Ansher SS, Dolan P, Bueding E. Biochemical effects of dithiolthiones. Food Chem Toxicol 1986; 24: 405–415
   PubMed Web of Science ®Google Scholar
• Ansher SS, Dolan P, Bueding E. Chemoprotectibe effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity. Hepatology 1983; 3: 932–935
   PubMed Web of Science ®Google Scholar
• Roebuck BD, Liu YL, Rogers AE, Groopman JD, Kensler TW. Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res 1991; 51: 5501–5506
   PubMed Web of Science ®Google Scholar
• Bolton MG, Munoz A, Jacobson LP, Groopman JD, Maxuitenko YY, Roebuck BD, Kensler TW. Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. Cancer Res 1993; 53: 3499–3504
   PubMed Web of Science ®Google Scholar
• Ali HM, Homeida MM, Sulaiman SM, Bennett JL. Diet-controlled blood levels of oltipraz in healthy male subjects. J Antimicrob Chemother 1984; 13: 465–470
   PubMed Web of Science ®Google Scholar
• Berezin FK, Ratain MJ, Benson AB, III. Pharmacokinetic study of 4-methyl-5-(-2-pyrazinyl)-1,2-dithiole-3-thione (oltipraz) in normal volunteers. Proc Am Assoc Cancer Res 1992; 33: 1244
   Google Scholar
• O'Dwyer PJ, Clayton M, Halbherr T, Myers CB, Yao K. Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells. Clin Cancer Res 1997; 3: 783–791
   PubMed Web of Science ®Google Scholar
• O'Dwyer PJ, Szarka CE, Yao KS. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Investig 1996; 98: 1210–1217
   PubMed Web of Science ®Google Scholar
• Benson AB, III, Olopade OI, Ratain MJ, Rademaker A, Mobarhan S, Stucky-Marshall L, French S, Dolan ME. Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon pelyps and first degree female relatives of breast cancer patients. Clin Cancer Res 2000; 6: 3870–3877
   PubMed Web of Science ®Google Scholar
• Langouet S, Furge LL, Kerriguy N, Nakamura K, Guillouzo A, Guengerich FP. Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. Chem Res Toxicol 2000; 13: 245–252
   PubMed Web of Science ®Google Scholar
• Langouet S, Coles B, Morel F, Becquemont L, Beaune P, Guengerich FP, Ketterer B, Guillouzo A. Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture. Cancer Res. 1995; 55: 5574–5579
   PubMed Web of Science ®Google Scholar
• Sofowora GG, Choo EF, Mayo G, Shyr Y, Wilkinson GR. In vivo inhibition of human CYP1A2 activity by oltipraz. Cancer Chemother Pharmacol 2001; 47: 505–510
   PubMed Web of Science ®Google Scholar
• Jacobson LP, Zhang BC, Zhu YR, Wang JB, Wu. Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev 1997; 6(4)257–265
   PubMed Web of Science ®Google Scholar
• Kensler TW, He X, Otieno M, Egner PA, Jacobson LP, Chen B, Wang JS, Zhu YR, Zhang BC, Wang JB, Wu Y, Zhang QN, Qian GS, Kuang SY, Fang X, Li YF, Yu LY, Prochaska HJ, Davidson NE, Gordon GB, Gorman MB, Zarba A, Enger C, Munoz A, Helzlsouer KJ. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol Biomarkers Prev 1998; 7: 127–134
   PubMed Web of Science ®Google Scholar
• Wang JS, Qian GS, Zarba A, He X, Zhu YR, Zhang BC, Jacobson L, Gange SJ, Munoz A, Kensler TW. Temporal patterns of aflatoxin–albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong Couny, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1996; 5(4)253–261
   PubMed Web of Science ®Google Scholar
• Chernomorsky S, Rancourt R, Virdi K, Segelman A, Poretz RD. Antimutagenicity, cytotoxicity and composition of chlorophyllin copper complex. Cancer Lett 1997; 120: 141–147
   PubMed Web of Science ®Google Scholar
• Dashwood R, Negishi T, Hayatsu H, Breinholt V, Hendricks J, Bailey G. Chemopreventive properties of chlorophylls towards aflatoxin B1: a review of the antimutagenicity and anticarcinogenicity data in rainbow trout. Mutat Res 1998; 399: 245–253
   PubMed Web of Science ®Google Scholar
• Dashwood RH. Protection by chlorophyllin against the covalent binding of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) to rat liver DNA. Carcinogenesis 1992; 13: 113–118
   PubMed Web of Science ®Google Scholar
• Breinholt V, Schimerlik M, Dashwood R, Bailey G. Mechanisms of chlorophyllin anticarcinogenesis against aflatoxin B1: complex formation with the carcinogen. Chem Res Toxicol 1995; 8: 506–514
   PubMed Web of Science ®Google Scholar
• Kamat JP, Boloor KK, Devasagayam TP. Chlorophyllin as an effective antioxidant against membrane damage in vitro and ex vivo. Biochim Biophys Acta 2000; 1487: 113–127
   PubMed Web of Science ®Google Scholar
• Yun CH, Jeong HG, Jhoun JW, Guengerich FP. Non-specific inhibition of cytochrome P450 activities by chlorophyllin in human and rat liver microsomes. Carcinogenesis 1995; 16: 1437–1440
   PubMed Web of Science ®Google Scholar
• Breinholt V, Arbogast D, Loveland P, Pereira C, Dashwood R, Hendricks J, Bailey G. Chlorophyllin chemoprevention in trout initiated by aflatoxin B (1) bath treatment: An evaluation of reduced bioavailability vs. target organ protective mechanisms. Toxicol Appl Pharmacol 1999; 158(2)14–151
   Google Scholar
• Egner PA, Stansbury KH, Snyder EP, Rogers ME, Hintz PA, Kensler TW. Identification and characterization of chlorin e(4) ethyl ester in sera of individuals participating in the chlorophyllin chemoprevention trial. Chem Res Toxicol 2000; 13: 900–906
   PubMed Web of Science ®Google Scholar
• Schwartz SJ, Lorenzo TV. Chlorophylls in foods. Crit Rev Food Sci Nutr 1990; 29: 1–17
   PubMed Web of Science ®Google Scholar
• Ferruzzi MG, Failla ML, Schwartz SJ. Sodium copper chlorophyllin: in vitro digestive stability and accumulation by Caco-2 human intestinal cells. J Agric Food Chem 2002; 50: 2173–2179
   PubMed Web of Science ®Google Scholar
• Chernomorsky S. Variability of the composition of chlorophyllin. Mutat Res 1994; 324: 177–178
   PubMed Web of Science ®Google Scholar
• Dashwood RH. The importance of using pure chemicals in (Anti) mutagenicity studies: Chlorophyllin as a case in point. Mutat Res 1997; 381: 283–286
   PubMed Web of Science ®Google Scholar